Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SARS and Avian Flu -- Ignore unavailable to you. Want to Upgrade?

To: Think4Yourself who wrote (2819)	10/18/2005 4:54:58 PM
From: Maurice Winn	Read Replies (1) \| Respond to of 4232

So it's a 30% death rate even with all the treatment available. <I have read numerous articles about treatment in the 117 infected. Most referenced 4 drugs for influenza: Relenza, Tamiflu, Amantadine, and another one I don't remember. I don't remember the other one, or speak of Amantadine, because all the articles said they have been shown to be ineffective against the current outbreak. They are still supposedly effective against other strains.> That means that when the treatment is out of stock, we revert to the old death rate, which was 70% [or maybe worse as those cases probably had some treatment too]. Unless we win the lottery and get the reduced mortality rate which often happens as bugs go through transitions, though they don't necessarily do so. This is like watching something the size of the Moon approaching Earth and we don't know yet whether it's going to score a bullseye or "miss by THAT much" [apologies to npr.org ] Mqurice